Loading company…
Pulmobiotics develops microbial treatments and vaccines for respiratory diseases.
Founded in 2020 as a spin-off from the Centre for Genomic Regulation in Barcelona, Pulmobiotics develops treatments and vaccines for respiratory diseases using microbial engineering and synthetic biology. Its platform uses attenuated lung bacteria to deliver antigens or therapeutic agents locally. In December 2022, it received EUR 1.9 million in grant funding from the European Innovation Council.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in